Hemophilia A Treatments
Find Hemophilia A Treatments
Brand Name
Cyklokapron
Generic Name
TRanexamic
View Brand Information FDA approval date: December 30, 1986
Classification: Antifibrinolytic Agent
Form: Injection, Tablet
What is Cyklokapron (TRanexamic)?
Tranexamic Acid Tablets are indicated for the treatment of cyclic heavy menstrual bleeding in females of reproductive potential. Tranexamic Acid Tablets are an antifibrinolytic indicated for the treatment of cyclic heavy menstrual bleeding in females of reproductive potential.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs
Summary: The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treati...
Prevention of Postpartum Hemorrhage: Pharmacokinetics (PK) Abd Pharmacodynamics (PD) of Tranexamic Acid
Summary: In part 1 of the study, the investigators conducted a prospective, open-label, dose finding pharmacokinetic (PK) study in 43 pregnant 3rd trimester women scheduled for non-emergent cesarean section. The investigators administered three doses of the drug (5 mg/kg, 10 mg/kg and 15 mg/kg) in an escalating fashion by cohort with the lowest dose first. The drug was administered intravenously at the tim...
Effects of Photobiomodulation With Red and Infrared Low-level Laser Diodes in Individuals Undergoing Rhinoplasty at a Single Centre: Protocol for a Randomized, Double-blind, Controlled Clinical Trial
Summary: This single-centre, randomized, double-blind, sham-controlled clinical trial evaluates whether preoperative photobiomodulation (PBM) with red and infrared light can reduce early postoperative periorbital edema in patients undergoing primary open rhinoplasty with osteotomies. Sixty participants will be randomly assigned to receive active PBM or sham PBM one hour before surgery. The primary outcome ...
Related Latest Advances
Brand Information
Cyklokapron (tranexamic acid)
WARNING: RISK OF MEDICATION ERRORS DUE TO INCORRECT ROUTE OF ADMINISTRATION
CYKLOKAPRON is for intravenous use only. Serious, including fatal, adverse reactions including seizures and cardiac arrythmias have occurred when CYKLOKAPRON was inadvertently administered via the neuraxial route
1INDICATIONS AND USAGE
CYKLOKAPRON
2DOSAGE FORMS AND STRENGTHS
Injection: 1,000 mg/10 mL (100 mg/mL) clear and colorless solution in single-dose ampules
Injection: 1,000 mg/10 mL (100 mg/mL) clear and colorless solution in single-dose vials
3CONTRAINDICATIONS
CYKLOKAPRON Injection is contraindicated:
- As a neuraxial (i.e., intrathecal, epidural) injection
- In patients with subarachnoid hemorrhage. Anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by CYKLOKAPRON in such patients.
- In patients with active intravascular clotting
- In patients with hypersensitivity to tranexamic acid or any of the ingredients
4ADVERSE REACTIONS
The following clinically significant adverse reactions are described elsewhere in the labeling:
- Risk of Medication Errors Due to Incorrect Route of Administration
- Thromboembolic Risk
- Seizures
- Hypersensitivity Reactions
- Visual Disturbances
- Dizziness
4.1Postmarketing Experience
The following adverse reactions have been identified during postapproval use of tranexamic acid. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Gastrointestinal disturbances (nausea, vomiting, diarrhea) may occur and may resolve with dose-reduction. Allergic dermatitis and giddiness have been reported. Hypotension has been reported when intravenous injection is too rapid.
Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, cerebral thrombosis, acute renal cortical necrosis, and central retinal artery, vein obstruction and cases associated with concomitant use of combination hormonal contraceptives) have been rarely reported in patients receiving tranexamic acid for indications other than hemorrhage prevention in patients with hemophilia. Convulsion, chromatopsia, and visual impairment have also been reported.
Anaphylaxis or anaphylactoid reactions have been reported that are suggestive of a causal relationship.
5OVERDOSAGE
Cases of overdosage of CYKLOKAPRON have been reported. Based on these reports, symptoms of overdosage may be gastrointestinal, e.g., nausea, vomiting, diarrhea; hypotensive, e.g., orthostatic symptoms; thromboembolic, e.g., arterial, venous, embolic; neurologic, e.g., visual impairment, convulsions, headache, mental status changes; myoclonus; and rash.
6DESCRIPTION
Tranexamic acid is trans-4-(aminomethyl)cyclohexanecarboxylic acid, an antifibrinolytic agent. Tranexamic acid is a white crystalline powder. The structural formula is
Empirical Formula: C
Each mL of the sterile solution for intravenous injection contains 100 mg tranexamic acid and Water for Injection to 1 mL. The aqueous solution for injection has a pH of 6.5 to 8.0.
7HOW SUPPLIED/STORAGE AND HANDLING
CYKLOKAPRON Injection is a clear and colorless solution supplied in the following presentations:
Store at 20ºC to 25°C (68ºF to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
8PRINCIPAL DISPLAY PANEL - 10 mL Ampule Label
Pfizer
NDC 0013-1114-01
10 mL ampule
Cyklokapron
1,000 mg/10 mL
(100 mg/mL)
PAA221603
9PRINCIPAL DISPLAY PANEL - 10 mL Ampule Carton - NDC 0013-1114-01
NDC 0013-1114-01
Contains 1 Ampule 10 mL
1000 mg/10 mL
(100 mg/mL)
(100 mg/mL)
Solution for intravenous injection
Single-Dose ONLY
Rx only
Pfizer Injectables
10PRINCIPAL DISPLAY PANEL - 10 mL Ampule Carton - NDC 0013-1114-15
NDC 0013-1114-15
Contains 1 Ampule 10 mL
Cyklokapron
1,000 mg/10 mL
Intravenous Use Only
Single-Dose Ampule
Rx only
Pfizer
11PRINCIPAL DISPLAY PANEL - 10 x 10 mL Ampule Box Label
NDC 0013-1114-10
Rx only
12PRINCIPAL DISPLAY PANEL - 10 mL Vial Label
NDC 0013-1114-20
10 mL Vial
Cyklokapron
1,000 mg/10 mL
(100 mg/mL)
Intravenous Use Only
13PRINCIPAL DISPLAY PANEL - 10 mL Vial Box
NDC 0013-1114-21
10 x 10 mL Vials
Cyklokapron
1,000 mg/10 mL (100 mg/mL)
Intravenous Use Only
Single-Dose Vial
Pfizer
TEAR HERE
